Damora Therapeutics (DMRA) director awarded 37,313 stock options

Rhea-AI Filing Summary

Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruno Julianne

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$23.05	03/23/2026		A		37,313		(1)	03/23/2036	Common Stock	37,313	$0.00	37,313	D

Explanation of Responses:

1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Garrett Winslow, attorney-in-fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Damora Therapeutics (DMRA) director Bruno Julianne report on this Form 4?

Director Bruno Julianne reported receiving a stock option grant for 37,313 shares of Damora Therapeutics common stock. The options were awarded as compensation and are not an open-market purchase, reflecting a new equity incentive tied to future service with the company.

What are the key terms of Bruno Julianne’s Damora Therapeutics stock option grant?

The grant covers options on 37,313 shares with a $23.05 exercise price per share. These options vest in equal monthly installments through March 23, 2029, and require Julianne to continue serving Damora Therapeutics for the options to become fully exercisable over time.

Is Bruno Julianne’s Form 4 transaction in DMRA stock a market buy or sell?

The Form 4 shows a grant of stock options, not a market buy or sell of DMRA shares. Code “A” indicates an award or other acquisition, meaning the company granted options as compensation rather than Julianne purchasing or selling shares on the open market.

How many Damora Therapeutics shares are covered by Bruno Julianne’s options after this filing?

After this award, Bruno Julianne holds options covering 37,313 underlying shares of Damora Therapeutics common stock directly. These options vest monthly through March 23, 2029, so the ability to exercise them builds gradually as service requirements to the company are satisfied.

When do Bruno Julianne’s Damora Therapeutics stock options expire?

The reported stock options expire on March 23, 2036, giving a long exercise window. Vesting occurs in equal monthly installments through March 23, 2029, so Julianne can exercise vested portions any time before expiration, subject to Damora Therapeutics’ applicable equity plan and policies.